TRI.TO -0.02C -1.89GFL.TO 2.01BRK.B -4.78PLUS -0.79TGTX 1.01LLY -33.23SU.TO 2.79
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

30.03
-0.39 (1.28%)
as of Oct 23, 2026, 8:00:00 pm Market Closed.
585 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
BUY

Pfizer Inc(PFE)

Feb 03, 2005
All the drug stocks in the US have dropped, but this had the best performance of all of them. Their Cellebrex has not been pulled and this has created some negatives. 3.2% yield and if it turns out the FDA finds no problem with the drug, it will be a major factor. Selling for 11 X earnings. Good price.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$23.91

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jan 31, 2005
FDA is becoming a lot more stricter with their criteria. Drug companies pipelines are a little bit thin now. A lot of competition. Valuations are cheaper than they've ever been. May not see any gains for a while.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$24.16

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 24, 2005
The industry as a whole has been in a difficult time. A lot of the stuff has been discounted in the stock. Trading at a very cheap multiple. Lots of cash and a high dividend yield. Good long term hold 4/5 years.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$24.26

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 21, 2005
A tough BUY, but given the valuation, if you have a 3/5 year time horizon the positives outweigh the negatives.
Photo of George LougheryGeorge Loughery
Owned
Unlock Rating
$24.48

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jan 20, 2005
Big pharmas have suffered because generics have come out of nowhere and have moved up to 50% of their business. The shine is coming off these companies and their credibility. Now trading at 12 X earnings and have a ton of cash, so could be buying back shares and improve its dividend. Good yield, but limited growth.
Photo of Ian AinsworthIan Ainsworth
No
Unlock Rating
$24.98

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 20, 2005
Could never understand the love for this stock as it was falling. It may have been oversold enough that it goes back up to $30 in the next 2 months. Long term, not very exciting.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$24.98

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 18, 2005
(A Top Pick Oct 26/04. Down 11%.) About a 50% differential between their model price and its present price. In their top 10. Has great value.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$25.30

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 12, 2005
If you look at what has happened to the pharnaceuticals over the last 2 years, generally the big ethical drug companies have been very poor performers. Growth rates have dropped to low single digits. Prefers bio-tech or bio-pharmaceuticals that have growth.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$26.03

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jan 05, 2005
Has been hurt by the Cox-2 inhibitor problem which is in their Celbrex and Bextra. Pharmaceutical stocks in general have all been poor performers and valuations have become more reasonable, so is probably OK to start looking at them. Prefers Bristol Myers as you get a nice size dividend as they wait for a pick up.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$26.27

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 24, 2004
(A Top Pick Oct 26/04. Down 8%.) Model price is $39. Totally mispriced. Should be a portion of everybody's portfolio. Looking out a year, you should make good money off it.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$26.07

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Dec 17, 2004
There was a negative call on one of their drugs which affected the stock price dramatically. This will mean a lot more testing and a lot more money. Have other products in their stable they can go with.
Photo of Robert FloydRobert Floyd
No
Unlock Rating
$25.75

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 17, 2004
When a stock gets hit with very negative news, there tends to be an overreaction, so it's best to put in a very lowball bid. If you get it there, fine, if not, you'll probably get a second chance.
Photo of David DremanDavid Dreman
No
Unlock Rating
$25.75

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Dec 17, 2004
Wait and see how things shake out. Only one day on the news and there's lots of interpretations on what it means.
Photo of Bill MacLachlanBill MacLachlan
No
Unlock Rating
$25.75

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 16, 2004
Biggest problem with the drugs has to do with the litigation problems in the US. George Bush has asked Congress to drastically reduce the awards. If successful, it will be a huge win for drug companies.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$28.98

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 16, 2004
Quality at a discount. There will be a lot of opportunity for upward surprises and multiple expansion. Trades at 11.7 X next year's earnings which is a 22% discount to its peer group. Have a wide and deep pipeline.
Photo of Paul Harris, CFAPaul Harris, CFA
Owned
Unlock Rating
$28.98

Stock price when the opinion was issued

$30.03

As of Oct 23, 2026. Market Closed.

biotechnologypharmaceutical
Showing 691 to 705 of 894 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

AMZN -2.38$248
META -6.23$642.62
VRT -1.27$194.32
WFC -0.62$82.39
ZS 17.39$255.15

Today's Top Picks

TRI.TO -0.02$172.41
C -1.89$120.62
GFL.TO 2.01$63.75
BRK.B -4.78$542.19
PLUS -0.79$95.36

Popular Articles

Latest Sell Signals

DOV 0$
BA 0.8$188.35
AC.TO -1.03$21.11
BB.TO 0.44$12.46
TSM 6.16$418.51

Most Recent Experts

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Jason Snipe, CIO, Odyssey Capital Advisors

Jason Snipe, CIO, Odyssey Capital Advisors

Odyssey Capital Advisors

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Tim Regan

Tim Regan

Kingwest & Company

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like